Breast HER2 Insitu Hybridization (HER2 ISH): Acceptable and unacceptable staining criteria impacting on interpretation

被引：0
|
作者：
Parry, S. [1 ]
Miller, K. [1 ]
Ibrahim, M. [1 ]
机构：
[1] UK NEQAS ICC & ISH, London, England
来源：
VIRCHOWS ARCHIV | 2012年 / 461卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
引用
收藏
页码：S258 / S258
页数：1
相关论文
共 50 条
  • [31] Correlation of In Situ HER2 RNA Expression With HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Categories in Breast Cancer
    Tseng, Yu-Fen
    Li, Yu-Chia
    Lee, Yi-Hsuan
    Hu, Hsiang-We
    Zhang, Man-San
    Hung, Tze-Chun
    Lien, Huang-Chun
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2024, 148 (03) : e48 - e56
  • [32] Reassessment of HER2 status in HER2 negative or HER2 unknown breast cancer patients with recurrent metastatic disease by analyzing serum HER2 and HER2 status of circulating tumor cells.
    Fehm, T.
    Lane, N.
    Solomayer, E.
    Wallwiener, D.
    Uhr, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S40 - S40
  • [33] The impact of modified staining method on HER2 immunohistochemical staining for HER2-low breast cancer
    Chen, Yen-Yin
    Yang, Ching-Fe
    Hsu, Chih-Yi
    PATHOLOGY, 2024, 56 (01) : 122 - 124
  • [34] HER2 0, HER2 1+and HER2 2+/FISH Negative Breast Cancers Are Biologically Different
    Mon, Khin Su
    Zhang, Hui
    Aragao, Alessa
    Tang, Ping
    LABORATORY INVESTIGATION, 2023, 103 (03) : S182 - S183
  • [35] Reassessment of HER2 status in breast cancer patients with initially HER2 negative or HER2 unknown primary tumors at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
    Fehm, T.
    Solomayer, E.
    Uhr, J.
    Wallwiener, D.
    ONKOLOGIE, 2008, 31 : 51 - 51
  • [36] HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer
    Zhao, Jing
    Krishnamurti, Uma
    Zhang, Chao
    Meisel, Jane
    Wei, Zhimin
    Suo, Aili
    Aneja, Ritu
    Li, Zaibo
    Li, Xiaoxian
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (11)
  • [37] Automation of staining and analysis of HER2 genotyping of breast carcinoma by fluorescence in situ hybridization (FISH)
    Tobbs, Raymond R.
    Pettay, James D.
    Swain, Eric
    Hicks, David G.
    Budd, G. Thomas
    Roche, Patrick C.
    Powell, William C.
    Grogan, Thomas M.
    MODERN PATHOLOGY, 2006, 19 : 24 - 24
  • [38] HER2 testing in metastatic breast cancer-Is reflex ISH testing necessary on HER2 IHC-equivocal (2+) cases?
    Liwski, Christopher R.
    Castonguay, Mathieu C.
    Barnes, Penny J.
    Rayson, Daniel
    Bethune, Gillian C.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2022, 59
  • [39] Prognostic significance and evolution of HER2 zero, HER2 low and HER2 positive in breast cancer after neoadjuvant treatment
    Wei, T.
    Wang, D.
    Peng, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S301 - S302
  • [40] Reproducibility of equivocal HER2 in situ hybridisation (ISH) results in invasive breast cancer, and correlation with HER2 mRNA expression as determined by Mammatyper®
    Riggi, J. A. M.
    Baez-Navarro, X.
    Zylberberg, D.
    van der Made, A.
    Dubois, D.
    Vanderveken, J.
    Benhaddi, N.
    Duhoux, F. P.
    Vernaeve, H.
    Vassilieff, M.
    Berliere, M.
    Galant, C.
    van Deurzen, C. H. M.
    van Bockstal, M. R.
    BREAST, 2025, 80
12345